Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Benitec Biopharma (BNTC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Disc Medicine (IRON – Research Report) and Benitec Biopharma (BNTC – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Disc Medicine (IRON)
In a report released yesterday, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Disc Medicine, with a price target of $100.00. The company’s shares closed last Friday at $55.95.
According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $122.33 average price target, representing a 70.8% upside. In a report issued on February 3, Morgan Stanley also maintained a Buy rating on the stock with a $120.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Benitec Biopharma (BNTC)
In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Benitec Biopharma. The company’s shares closed last Friday at $10.38.
According to TipRanks.com, Baral is a top 100 analyst with an average return of
Benitec Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $32.00.
